News: News

JAKARTA – On the occasion of the 61st National Health Day (HKN), Dexa Medica achieved a significant milestone by receiving the Karya Anak Bangsa Award from the Ministry of Health of the Republic of Indonesia, recognizing it as the pharmaceutical industry with the highest number of clinical trials for natural-based…

As global interest in herbal medicines continues to grow, only a limited number of products are developed with rigorous scientific methods and supported by strong clinical evidence. DLBS addresses this gap through the development of Integrative Modern Natural Medicines—therapeutics based on defined bioactive fractions with clear mechanisms of action and…

Minister of Health Budi Gunadi Sadikin has set a target for 60–70 million Indonesians to receive free health screenings by 2025. In support of this initiative, PT Dexa Medica continues to contribute through its Cek Segitiga Gratis program, which recently took place at the Car Free Day area on Boulevard…

Cikarang, October 16th, 2025 - A delegation from the World Health Organization (WHO) and Indonesia’s National Agency for Drug and Food Control (BPOM RI) visited Dexa Laboratories of Biomolecular Sciences (DLBS) to observe firsthand how Indonesia’s biodiversity is being utilized in pharmaceutical research for the development of Modern Indonesian Natural…

Dexa Medica once again demonstrates its strong commitment as a national pharmaceutical company that plays a vital role in strengthening Indonesia’s pharmaceutical independence, particularly through the development of natural-based medicines. This commitment was reflected in its active contribution to the prestigious 16th Annual Meeting of the WHO–International Regulatory Cooperation for…

Dexa Group achieved a remarkable milestone by receiving two prestigious awards in a single day, underscoring its commitment to ensuring halal assurance across all products and facilities. The recognitions came from Indonesia’s Ministry of Industry (Kemenperin) and the Halal Inspection Body of the Institute for Food, Drug, and Cosmetic Studies…

Non-Communicable Diseases (NCDs) such as hypertension, diabetes, and high cholesterol are increasingly becoming a threat to public health in Indonesia. These three silent killers often show no symptoms, yet have serious impacts on quality of life and healthcare costs. Responding to this challenge, PT Dexa Medica, through its Cek Segitiga…

Dexa Medica has once again received the prestigious Indonesia Most Reputable Companies Award 2025 from SWA Magazine and Business Digest. This marks the second time Dexa Medica has earned this recognition, reaffirming the company’s commitment to building and maintaining its reputation as a reflection of quality. The award was presented…

Dexa Medica has been awarded the 2025 Industrial Technology Pioneer Award (Rintek) in the category of Technology Pioneer Evaluation Results by the Ministry of Industry of the Republic of Indonesia. The award recognizes the success of Inlacin, an Indonesian Original Modern Medicine for diabetes, as a clinically proven global innovation…

Non-Communicable Diseases such as hypertension, diabetes, and high cholesterol are increasingly threatening public health in Indonesia. According to the Ministry of Health of the Republic of Indonesia, these three silent diseases are among the leading contributors to the national health burden and are often detected only when it is too…